Cargando…

Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion

Intravenous unfractionated heparin (UFH) remains one of the most commonly used anticoagulants in the hospital setting. The optimal protocol for initiation and maintenance of UFH has been difficult to determine. Over the past two decades, weight-based nomogram protocols have gained favor. Herein, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutfi, Forat, Bishnoi, Rohit, Patel, Vikas J, Elfasi, Aisha, Setteducato, Michael, Zhang, Shuyao, Shah, Chintan P, Kurian, Saji, Kamath, Chethana, Kim, Dae Jun, Zumberg, Marc S, Murphy, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325397/
https://www.ncbi.nlm.nih.gov/pubmed/32617214
http://dx.doi.org/10.7759/cureus.8339
_version_ 1783552142360969216
author Lutfi, Forat
Bishnoi, Rohit
Patel, Vikas J
Elfasi, Aisha
Setteducato, Michael
Zhang, Shuyao
Shah, Chintan P
Kurian, Saji
Kamath, Chethana
Kim, Dae Jun
Zumberg, Marc S
Murphy, Martina
author_facet Lutfi, Forat
Bishnoi, Rohit
Patel, Vikas J
Elfasi, Aisha
Setteducato, Michael
Zhang, Shuyao
Shah, Chintan P
Kurian, Saji
Kamath, Chethana
Kim, Dae Jun
Zumberg, Marc S
Murphy, Martina
author_sort Lutfi, Forat
collection PubMed
description Intravenous unfractionated heparin (UFH) remains one of the most commonly used anticoagulants in the hospital setting. The optimal protocol for initiation and maintenance of UFH has been difficult to determine. Over the past two decades, weight-based nomogram protocols have gained favor. Herein, we present a retrospective study of 377 patients at a single tertiary academic center treated with low intensity (LI) and standard intensity (SI) UFH protocols for therapeutic anticoagulation. UFH levels are measured by anti-Xa assay activity with therapeutic levels of 0.30 to 0.70 IU/mL for SI and 0.25 to 0.35 IU/mL for LI.  Patients treated on the LI protocol were more likely to have had a previous history of bleeding and lower baseline hemoglobin. Incidence of new or worsening thrombus while on UFH was comparable between both protocols (odds ratio (OR) 0.93, 95% confidence interval (CI) 0.29-2.98, p=0.899). Patients on LI protocol had higher incidence of bleeding while on UFH (OR 1.21, 95% CI 0.51-2.89, p=0.667). Our study thus suggests that the LI protocol may have comparable efficacy to the SI protocol in treating venous thromboembolism (VTE) and that target anti-Xa levels of 0.25 to 0.35 IU/mL may be more optimal in high-risk patients.
format Online
Article
Text
id pubmed-7325397
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-73253972020-07-01 Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion Lutfi, Forat Bishnoi, Rohit Patel, Vikas J Elfasi, Aisha Setteducato, Michael Zhang, Shuyao Shah, Chintan P Kurian, Saji Kamath, Chethana Kim, Dae Jun Zumberg, Marc S Murphy, Martina Cureus Internal Medicine Intravenous unfractionated heparin (UFH) remains one of the most commonly used anticoagulants in the hospital setting. The optimal protocol for initiation and maintenance of UFH has been difficult to determine. Over the past two decades, weight-based nomogram protocols have gained favor. Herein, we present a retrospective study of 377 patients at a single tertiary academic center treated with low intensity (LI) and standard intensity (SI) UFH protocols for therapeutic anticoagulation. UFH levels are measured by anti-Xa assay activity with therapeutic levels of 0.30 to 0.70 IU/mL for SI and 0.25 to 0.35 IU/mL for LI.  Patients treated on the LI protocol were more likely to have had a previous history of bleeding and lower baseline hemoglobin. Incidence of new or worsening thrombus while on UFH was comparable between both protocols (odds ratio (OR) 0.93, 95% confidence interval (CI) 0.29-2.98, p=0.899). Patients on LI protocol had higher incidence of bleeding while on UFH (OR 1.21, 95% CI 0.51-2.89, p=0.667). Our study thus suggests that the LI protocol may have comparable efficacy to the SI protocol in treating venous thromboembolism (VTE) and that target anti-Xa levels of 0.25 to 0.35 IU/mL may be more optimal in high-risk patients. Cureus 2020-05-28 /pmc/articles/PMC7325397/ /pubmed/32617214 http://dx.doi.org/10.7759/cureus.8339 Text en Copyright © 2020, Lutfi et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Lutfi, Forat
Bishnoi, Rohit
Patel, Vikas J
Elfasi, Aisha
Setteducato, Michael
Zhang, Shuyao
Shah, Chintan P
Kurian, Saji
Kamath, Chethana
Kim, Dae Jun
Zumberg, Marc S
Murphy, Martina
Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
title Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
title_full Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
title_fullStr Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
title_full_unstemmed Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
title_short Bleeding and Thrombotic Risk in Low Dose Heparin Infusion as Compared to Standard Dose Heparin Infusion
title_sort bleeding and thrombotic risk in low dose heparin infusion as compared to standard dose heparin infusion
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325397/
https://www.ncbi.nlm.nih.gov/pubmed/32617214
http://dx.doi.org/10.7759/cureus.8339
work_keys_str_mv AT lutfiforat bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT bishnoirohit bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT patelvikasj bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT elfasiaisha bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT setteducatomichael bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT zhangshuyao bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT shahchintanp bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT kuriansaji bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT kamathchethana bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT kimdaejun bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT zumbergmarcs bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion
AT murphymartina bleedingandthromboticriskinlowdoseheparininfusionascomparedtostandarddoseheparininfusion